The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
3925319
Glioblastoma organoids model extracellular matrix heterogeneity
Date
August 13, 2023
Explore related products in the following collection:
Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults with a prognosis of 12-15 months. The aggressiveness of GBM is highly attributed to its heterogeneity of the tumor microenvironment (TME). Current in vitro models of GBM offer limited translation to in vivo tumors because of the heterogeneous TME, leading to limited progress in drug development and treatment. Organoids are millimeter-scale, 3D in vitro modeling systems that recapitulate stem cell differentiation into highly organized, heterogeneous in vivo organ-like systems. Here, we used defined engineering parameters on single GSCs to grow and develop into GBM organoids (GBOs) with a diameter up to 4.0 mm in 3 months or less, without the use of media-induced differentiation or extracellular matrix (ECM) mimicking scaffolds. We found our GBOs self-induced differentiation and organized cells into some key components of the GBM TME (i.e. hypoxic niche, angiogenesis, and necrotic core). Interestingly, the GBOs also self-secreted and organized its own key ECM components (i.e. collagen IV, elastin, laminin, and hyaluronic acid). Through our studies, we aim to understand what induces GSC differentiation and ECM redesign to form the heterogeneous TME and how this dynamic TME leads to varying drug response.
Core fucosylation is a highly prevalent and significant feature of _N_-glycosylation in therapeutic monoclonal antibodies produced by mammalian cells where its absence (afucosylation) plays a key role in patient treatment safety and efficacy…
Mammalian cells are widely used in the pharmaceutical industry to produce vaccines and recombinant protein products such as monoclonal antibodies (mAbs)…
Metabolic flux analysis (MFA) can be used to understand metabolic signatures of CHO clones and identify bottlenecks for antibody productions. MFA utilizes 13C-labelled glucose in upstream process to quantitatively track metabolic flux in each pathway…
Many therapeutic proteins are produced using the Chinese hamster ovary (CHO) cell line due to their natural genetic plasticity, human-like post translational modifications, and superior production of secreted proteins…